Stroke, an immensely complicated cerebrovascular disease is harvesting lives of millions over the globe and has been designated as world’s second largest killer. Improvement of pre and post treatment for this pathology to reduce the death toll has become an urgency since there are very limited therapeutic options for stroke patients, while efforts to give direct neuro-protection to the brain cells on set of ischemic stroke has been hugely unsuccessful. As oxidative stress plays a key role in brain damage during this pathology and NOX enzymes are the main source reactive oxygen species inducing this stress, at present NOX inhibitors have come to lime light for treating this condition but available Nox inhibitors lack of certain qualities and exhibit side effects that hold them back form clinical trials. In this study in vitro efficacy of NOX inhibitors M4, M107 and M114 patented by Glucox Biotech AB was evaluated along with a positive control, VAS2870, in cellular model of ischemic stroke using the T98G cell line through detection of gene expression of Nox2/4 genes, cell viability assay and ROS assay. Results indicate that these inhibitors decrease cell mortality significantly by inhibiting the enzymes activity and lowering the ROS. In the future there is great hope that these inhibitors could be used clinically due to their uniqueness and may hold the key to ameliorate the suffering from stroke, and save lives.